Objective
to report the 6-year clinical outcome of the impact of IABP in cardiogenic shock as compared to a control group in patients with acute myocardial infarction
Study
an open-label, prospective, multicentre study
Population
patients with cardiogenic shock and planned early revascularisation preferably by PCI
Endpoints
all-cause mortality at 6.2 years
Conclusion
IABP has no beneficial effect on the longterm all-cause mortality in patients with acute MI complicated by cardiogenic shock
Thiele et al. Circulation. 2019;139:395-403
